Summarized by Masters of Longevity from Longevity Technology.
A Phase 1 patient received extended autologous NK cell therapy outcomes.
Key Takeaways
- Troculeucel is an autologous NK cell therapy in Phase 1.
- The patient received 12 months of open‑label Troculeucel treatment.
- A single‑subject poster will report long‑term cognitive observations.
